Net Profit Margin: 11.96%
Is the net profit margin high or low?
The net profit margin of 11.96% is 40% above its 5-year average of 8.56%, around the middle of its 5-year range (-11.69%–38.61%).
As of Thursday, June 25, 2026. 27.20% above its 12-month average of 9.40%.
PODD Profit Margin
Reported quarterly profit margin; no daily interpolation.
PODD Average Net Profit Margin Chart
PODD Current vs Average Net Profit Margin Chart
PODD Net Profit Margin Metrics
NET PROFIT MARGIN
11.96%
NET PROFIT MARGIN AVG TTM
9.40%
NET PROFIT MARGIN AVG 3Y
11.30%
NET PROFIT MARGIN AVG 5Y
9.02%
NET PROFIT MARGIN AVG 10Y
2.38%
NET PROFIT MARGIN AVG 15Y
-4.94%
NET PROFIT MARGIN AVG 20Y
-10.29%
CURRENT VS TTM AVG
+27.20%
CURRENT VS 3Y AVG
+5.87%
CURRENT VS 5Y AVG
+32.61%
CURRENT VS 10Y AVG
+403.42%
CURRENT VS 15Y AVG
+342.31%
CURRENT VS 20Y AVG
+216.19%
PODD Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Insulet Corp. (PODD) | $10.31B | 11.96% | 9.40% | 11.30% | 9.02% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -4.07% | -4.03% | -0.72% | 0.14% |
| Baxter International Inc. (BAX)vs › | $10.87B | -9.70% | -7.30% | -3.29% | 1.14% |
| Charles River Laboratories International, Inc. (CRL)vs › | $9.73B | -4.59% | -1.67% | 5.09% | 7.31% |
| Henry Schein, Inc. (HSIC)vs › | $9.55B | 2.95% | 3.05% | 3.43% | 3.79% |
| Revvity, Inc. (RVTY)vs › | $11.78B | 8.30% | 9.60% | 8.02% | 12.66% |
| Align Technology, Inc. (ALGN)vs › | $12.24B | 10.50% | 10.36% | 10.48% | 22.21% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.57B | 6.52% | -21.22% | -48.94% | 16.61% |
| Oscar Health, Inc. (OSCR)vs › | $7.56B | -0.30% | -1.75% | -5.71% | -20.27% |
| Solventum Corporation (SOLV)vs › | $13.09B | 17.33% | 12.25% | 14.36% | 15.15% |
Margin Comparison
Operating Margin
17.5%
Net Profit Margin
12.0%
Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Net Profit Margin FAQ
- What is the net profit margin for Insulet Corp. (PODD)?
- The net profit margin for PODD stock is 11.96%.
- Is Insulet Corp.'s net profit margin high or low?
- The net profit margin of 11.96% is 40% above its 5-year average of 8.56%, around the middle of its 5-year range (-11.69%–38.61%).
- What is the TTM average net profit margin for Insulet Corp. (PODD)?
- The TTM average net profit margin for PODD stock is 9.40%.
- What is the 3Y average net profit margin for Insulet Corp. (PODD)?
- The 3Y average net profit margin for PODD stock is 11.30%.
- What is the 5Y average net profit margin for Insulet Corp. (PODD)?
- The 5Y average net profit margin for PODD stock is 9.02%.
- What is the 10Y average net profit margin for Insulet Corp. (PODD)?
- The 10Y average net profit margin for PODD stock is 2.38%.
- What is the 15Y average net profit margin for Insulet Corp. (PODD)?
- The 15Y average net profit margin for PODD stock is -4.94%.
- What is the 20Y average net profit margin for Insulet Corp. (PODD)?
- The 20Y average net profit margin for PODD stock is -10.29%.
PODD Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-03-31 | 11.96% |
| 2025-12-31 | 12.96% |
| 2025-09-30 | 12.40% |
| 2025-06-30 | 3.47% |
| 2025-03-31 | 6.22% |
| 2024-12-31 | 16.85% |
| 2024-09-30 | 14.25% |
| 2024-06-30 | 38.61% |
| 2024-03-31 | 11.66% |
| 2023-12-31 | 20.26% |
| 2023-09-30 | 11.99% |
| 2023-06-30 | 6.89% |
| 2023-03-31 | 6.65% |
| 2022-12-31 | 4.60% |
| 2022-09-30 | -1.53% |
| 2022-06-30 | -11.69% |
| 2022-03-31 | 9.41% |
| 2021-12-31 | 9.49% |
| 2021-09-30 | 4.57% |
| 2021-06-30 | -9.50% |
| 2021-03-31 | 0.24% |
| 2020-12-31 | -6.95% |
| 2020-09-30 | 4.96% |
| 2020-06-30 | 6.36% |
| 2020-03-31 | -1.06% |
| 2019-12-31 | 2.37% |
| 2019-09-30 | 0.42% |
| 2019-06-30 | 0.79% |
| 2019-03-31 | 2.76% |
| 2018-12-31 | 6.00% |
| 2018-09-30 | 1.10% |
| 2018-06-30 | -1.36% |
| 2018-03-31 | -5.32% |
| 2017-12-31 | -5.26% |
| 2017-09-30 | -1.83% |
| 2017-06-30 | -7.08% |
| 2017-03-31 | -9.81% |
| 2016-12-31 | -8.80% |
| 2016-09-30 | -3.25% |
| 2016-06-30 | -4.81% |
| 2016-03-31 | -15.37% |
| 2015-12-31 | -27.29% |
| 2015-09-30 | -21.68% |
| 2015-06-30 | -20.42% |
| 2015-03-31 | -19.33% |
| 2014-12-31 | -7.44% |
| 2014-09-30 | -14.46% |
| 2014-06-30 | -40.42% |
| 2014-03-31 | -8.88% |
| 2013-12-31 | -3.65% |
| 2013-09-30 | -34.84% |
| 2013-06-30 | -17.50% |
| 2013-03-31 | -18.59% |
| 2012-12-31 | -17.63% |
| 2012-09-30 | -22.68% |
| 2012-06-30 | -28.36% |
| 2012-03-31 | -30.95% |
| 2011-12-31 | -30.38% |
| 2011-09-30 | -30.41% |
| 2011-06-30 | -60.30% |
| 2011-03-31 | -34.85% |
| 2010-12-31 | -75.12% |
| 2010-09-30 | -47.53% |
| 2010-06-30 | -59.78% |
| 2010-03-31 | -66.59% |
| 2009-12-31 | -73.88% |
| 2009-09-30 | -131.97% |
| 2009-06-30 | -138.46% |
| 2009-03-31 | -157.55% |
| 2008-12-31 | -238.45% |
| 2008-09-30 | -205.26% |
| 2008-06-30 | -321.99% |
| 2008-03-31 | -297.92% |
| 2007-12-31 | -359.28% |
| 2007-09-30 | -359.77% |
| 2007-06-30 | -394.52% |
| 2007-03-31 | -575.70% |
| 2006-12-31 | -663.01% |
| 2006-09-30 | -1239.91% |
| 2006-06-30 | -1239.91% |
| 2006-03-31 | -1239.91% |
| 2005-12-31 | 0.00% |
| 2005-09-30 | 0.00% |
| 2005-06-30 | 0.00% |
| 2005-03-31 | 0.00% |
Related Metrics
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy